Tim Surgenor works closely with the leadership teams of rapidly growing biotech companies to advance strategy, communications, and business development. At Red Sky he has led strategy, commercial assessment and business development assignments for a number of clinical stage companies and has had long term advisory relationships with Acetylon Pharmaceuticals, Aldeyra Therapeutics and Ironwood Pharmaceuticals.
Tim is a founder and managing partner of Red Sky and has more than 30 years of general management experience in biotech and healthcare companies, with roles including public company CFO, CEO and board member. Previously, Tim was Executive Vice President of Haemonetics, where he ran business development and global marketing and led numerous technology and company acquisitions. As President of Genzyme’s Tissue Repair Division, he led the worldwide launch of several cellular therapy products and was a member of the Genzyme Corporation’s investor relations and financing team. Tim has also served as CEO of Cyberkinetics, a publicly traded neurotechnology company and CFO of BioSurface Technology, a publicly traded cell therapy company. He is currently board member and audit committee chair of Neurometrix.
Tim has an MBA from the Harvard Graduate School of Business Administration a BA in Biochemistry from Williams College.